日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

比美替尼和恩科拉非尼治疗携带非V600E BRAF突变的晚期实体瘤:来自II期BEAVER试验的结果

April A N Rose #,Jennifer Maxwell #,Emmanuelle Rousselle #,Chantel L Mukonoweshuro,Islam E Elkholi,Melody Riaud,Marco Biondini,Erica Cianfarano,Isabel Soria-Bretones,Chantal Tobin,Meghan McGuire,Rhoda W Y Law,Andrew J Elia,Ben X Wang,Ian King,Tong Zhang,Trevor J Pugh,Zaid Saeed Kamil,Marcus Butler,Frances A Shepherd,Natasha B Leighl,Albiruni Abdul Razak,Aaron Hansen,Samuel D Saibil,Philippe L Bedard,Peter M Siegel,Lillian L Siu,David W Cescon,Anna Spreafico

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer

一项针对晚期/转移性复发性胆道癌患者的Ib期多中心研究,评估抗TIM-3(S095018/Sym023)联合抗PD-1(Sym021)的疗效。

Ghiringhelli, Francois; Kim, Richard; Macarulla, Teresa; Moreno, Irene; Abdul Razak, Albiruni; Rodon Ahnert, Jordi; Liao, Chih-Yi; Davis, Sarah Lindsey; Mahipal, Amit; Marron, Thomas; Raimbourg, Judith; Kaplon, Hélène; Geronimi, Julia; Harouki, Najah; Rodrigues, Christelle; Darcel, Pauline; Jakobsen, Janus Schou; Skartved, Niels; Hald, Rikke; Lopez-Ravnborg, Daleen; He, Peng; Ianopoulos, Xenophon; Askoxylakis, Vasileios; Lakhani, Nehal

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab

组织非特异性全基因组甲基化组富集检测方法的临床验证,用于监测帕博利珠单抗的疗效

Stutheit-Zhao, Eric Y; Zhong, Yongqi; Melton, Collin A; Lightbody, Elizabeth D; Hinterberg, Michael A; Wang, Yarong; Hall, Owen; Sosa, Eduardo V; Provance, Jeremy B; Zhang, Junjun; Licon, Abel; Liu, Zhihui Amy; Abdul Razak, Albiruni R; Spreafico, Anna; Bedard, Philippe L; Hansen, Aaron R; Lheureux, Stephanie; Ohashi, Pamela S; Williams, Alan; Bratman, Scott V; Allen, Brian A; Zhang, Jing; De Carvalho, Daniel D; Hartman, Anne-Renee; Siu, Lillian L; Sanz-Garcia, Enrique

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies

KPT-9274(一种首创的PAK4和NAMPT双重抑制剂)在晚期实体恶性肿瘤患者中的首次人体I期研究

Razak, Albiruni; Mahipal, Amit; Diamond, Jennifer R; Ribas, Antoni; Berlin, Jordan David; Azmi, Asfar S; Mark, Tomer; Walker, Christopher J; Chai, Yi; Kashyap, Trinayan; Gudi, Girish; Naing, Aung

Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

INTRIGUE 研究的最终总生存期分析:瑞普替尼与舒尼替尼治疗胃肠道间质瘤患者的总体生存期和长期安全性更新

Heinrich, Michael C; Blay, Jean-Yves; Gelderblom, Hans; George, Suzanne; Schöffski, Patrick; von Mehren, Margaret; Zalcberg, John R; Jones, Robin L; Kang, Yoon-Koo; Razak, Albiruni Abdul; Trent, Jonathan; Attia, Steven; Le Cesne, Axel; Boye, Kjetil; Goldstein, David; Sánchez, César; Siontis, Brittany L; Cox, Paulina; Davis, Erika; Sherman, Matthew L; Ruiz-Soto, Rodrigo; Bauer, Sebastian

Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study

肿瘤内注射INT230-6治疗晚期实体瘤成年患者的安全性和有效性:一项开放标签1/2期剂量递增研究的结果

Thomas, Jacob S; Siu, Lillian L; Ingham, Matthew; Azad, Nilofer S; Meyer, Christian F; Olszanski, Anthony J; Whalen, Giles F; Camacho, Luis H; Hu, James S; Hanna, Diana L; Cheng, Phillip M; Abdul Razak, Albiruni R; Abbate, Franco; Mahmood, Syed; Walters, Ian B; Bender, Lewis H; El-Khoueiry, Anthony B

Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors

接受免疫检查点抑制剂治疗的重症肌无力患者

Alghabban, Abdulrahman; Corke, Lucy; Katzberg, Hans; Bril, Vera; Barnett-Tapia, Carolina; Mason, Warren; Alothman, Raed; Albiruni Ryan, Abdul Razak; Hogg, David; Sridhar, Srikala; Dhani, Neesha; Spreafico, Anna; Eng, Lawson; Sacher, Adrian; Bradbury, Penelope; Liu, Geoffrey; Leighl, Natasha; Shepherd, Frances A

Epidemiology, Treatment Patterns, Survival, Healthcare Resource Utilization, and Costs of Dedifferentiated Liposarcoma (DDLPS) in Canada: A Retrospective Cohort Study Using Administrative Databases in Ontario

加拿大去分化脂肪肉瘤 (DDLPS) 的流行病学、治疗模式、生存率、医疗资源利用情况和费用:一项基于安大略省行政数据库的回顾性队列研究

Seung, Soo Jin; Wong, Anisia; Milan, Raymond; Chandran, Nisha; Razak, Albiruni R Abdul

First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies

针对晚期实体恶性肿瘤患者开展的 23ME-00610(一种针对经基因验证的 CD200R1 免疫检查点的拮抗抗体)的首次人体研究

Kummar, Shivaani; Razak, Albiruni Abdul; Laurie, Scott; Glatt, Dylan M; Kell, Sariah; Diep, Anh N; Schmidt, Maike; Hom, Clifford; German, Chris; Shringarpure, Suyash S; Majeed, Sophia R; Rasco, Drew

First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors

首次人体研究评估抗GDF15抗体AZD8853在晚期/转移性实体瘤患者中的安全性和有效性

Carneiro, Benedito A; Gbolahan, Olumide B; Abdul Razak, Albiruni Abdul; Hilton, John F; Lambert, Arthur W; Hood, John; Pluta, Michael; Bragulat, Veronique; Sanai, Elhan; Kumar, Rakesh; Jodrell, Duncan I; LoRusso, Patricia M